[{"id":"25bdc19a-f615-4b75-bbf6-347f595503e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320081","created_at":"2022-04-11T13:52:48.178Z","updated_at":"2024-07-02T16:36:13.225Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma","source_id_and_acronym":"NCT05320081","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • anti-CD30 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-04-11"}]